275 related articles for article (PubMed ID: 26788719)
1. Population health impact of statin treatment in Canada.
Hennessy DA; Tanuseputro P; Tuna M; Bennett C; Perez R; Shields M; Ko DT; Tu J; Manuel DG
Health Rep; 2016 Jan; 27(1):20-8. PubMed ID: 26788719
[TBL] [Abstract][Full Text] [Related]
2. Comparing Guidelines for Statin Treatment in Canada and the United States.
Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
[TBL] [Abstract][Full Text] [Related]
3. Time to improve statin prescription guidelines in low-risk patients?
Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
[TBL] [Abstract][Full Text] [Related]
5. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study.
Manuel DG; Kwong K; Tanuseputro P; Lim J; Mustard CA; Anderson GM; Ardal S; Alter DA; Laupacis A
BMJ; 2006 Jun; 332(7555):1419. PubMed ID: 16737980
[TBL] [Abstract][Full Text] [Related]
7. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
8. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.
Ueda P; Lung TW; Clarke P; Danaei G
Br J Gen Pract; 2017 Sep; 67(662):e598-e608. PubMed ID: 28760741
[TBL] [Abstract][Full Text] [Related]
9. Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
Ko MJ; Kim YJ; Park CM; Lee SM; Lee WJ; Pencina MJ; Navar-Boggan AM; Park DW
Am Heart J; 2015 Sep; 170(3):598-605.e7. PubMed ID: 26385045
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses.
Garg N; Muduli SK; Kapoor A; Tewari S; Kumar S; Khanna R; Goel PK
Indian Heart J; 2017; 69(4):458-463. PubMed ID: 28822511
[TBL] [Abstract][Full Text] [Related]
11. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
12. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?
Burgers LT; Nauta ST; Deckers JW; Severens JL; Redekop WK
Int J Cardiol; 2014 Oct; 176(3):980-7. PubMed ID: 25217221
[TBL] [Abstract][Full Text] [Related]
13. Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England.
Ueda P; Lung TW; Lu Y; Salomon JA; Rahimi K; Clarke P; Danaei G
PLoS One; 2018; 13(3):e0190688. PubMed ID: 29561843
[TBL] [Abstract][Full Text] [Related]
14. The 2006 Canadian dyslipidemia guidelines will prevent more deaths while treating fewer people--but should they be further modified?
Manuel DG; Wilson S; Maaten S
Can J Cardiol; 2008 Aug; 24(8):617-20. PubMed ID: 18685741
[TBL] [Abstract][Full Text] [Related]
15. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.
Robinson T; Jackson R; Wells S; Kerr A; Marshall R
N Z Med J; 2017 Oct; 130(1463):28-38. PubMed ID: 28981492
[TBL] [Abstract][Full Text] [Related]
16. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
17. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.
Laleman N; Henrard S; van den Akker M; Goderis G; Buntinx F; Van Pottelbergh G; Vaes B
BMC Cardiovasc Disord; 2018 Nov; 18(1):209. PubMed ID: 30400778
[TBL] [Abstract][Full Text] [Related]
18. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively.
McElduff P; Jaefarnezhad M; Durrington PN
Heart; 2006 Sep; 92(9):1213-8. PubMed ID: 16717068
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
